[go: up one dir, main page]

WO1999012964A3 - Kay, nouvelle proteine du systeme immunitaire - Google Patents

Kay, nouvelle proteine du systeme immunitaire Download PDF

Info

Publication number
WO1999012964A3
WO1999012964A3 PCT/US1998/019037 US9819037W WO9912964A3 WO 1999012964 A3 WO1999012964 A3 WO 1999012964A3 US 9819037 W US9819037 W US 9819037W WO 9912964 A3 WO9912964 A3 WO 9912964A3
Authority
WO
WIPO (PCT)
Prior art keywords
kay
immune system
system protein
novel immune
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/019037
Other languages
English (en)
Other versions
WO1999012964A2 (fr
Inventor
Jurg Tschopp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL13448098A priority Critical patent/IL134480A0/xx
Priority to EA200000311A priority patent/EA200000311A1/ru
Priority to BR9812433-1A priority patent/BR9812433A/pt
Priority to JP2000510769A priority patent/JP2001515711A/ja
Priority to SK353-2000A priority patent/SK3532000A3/sk
Priority to CA002303424A priority patent/CA2303424A1/fr
Priority to AU93152/98A priority patent/AU9315298A/en
Priority to EEP200000148A priority patent/EE200000148A/xx
Priority to KR1020007002576A priority patent/KR20010023892A/ko
Application filed by Biogen Inc filed Critical Biogen Inc
Priority to HU0004034A priority patent/HUP0004034A3/hu
Priority to EP98946052A priority patent/EP1012270A2/fr
Publication of WO1999012964A2 publication Critical patent/WO1999012964A2/fr
Publication of WO1999012964A3 publication Critical patent/WO1999012964A3/fr
Priority to IS5375A priority patent/IS5375A/is
Priority to NO20001240A priority patent/NO20001240L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention se rapporte à Kay, nouveau membre de la famille des facteurs de nécrose des tumeurs (TNF), à des ligands Kay modifiés et à des compositions pharmaceutiques qui les renferment.
PCT/US1998/019037 1997-09-12 1998-09-11 Kay, nouvelle proteine du systeme immunitaire Ceased WO1999012964A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
KR1020007002576A KR20010023892A (ko) 1997-09-12 1998-09-11 Ｋａｙ-신규 면역계 단백질
BR9812433-1A BR9812433A (pt) 1997-09-12 1998-09-11 Kay- uma proteìna do sistema de imunização
JP2000510769A JP2001515711A (ja) 1997-09-12 1998-09-11 Ｋａｙ−新規の免疫系タンパク質
SK353-2000A SK3532000A3 (en) 1997-09-12 1998-09-11 Dna sequence coding for kay ligand, method for the preparation of kay ligand, pharmaceutical composition containing said ligand and the use thereof
CA002303424A CA2303424A1 (fr) 1997-09-12 1998-09-11 Kay, nouvelle proteine du systeme immunitaire
AU93152/98A AU9315298A (en) 1997-09-12 1998-09-11 Kay - a novel immune system protein
EEP200000148A EE200000148A (et) 1997-09-12 1998-09-11 Kay - uus immuunsüsteemi valk
IL13448098A IL134480A0 (en) 1997-09-12 1998-09-11 Kay - an immune system protein and dna sequences encoding the same
HU0004034A HUP0004034A3 (en) 1997-09-12 1998-09-11 Kay - a novel immune system protein
EA200000311A EA200000311A1 (ru) 1997-09-12 1998-09-11 Новый белок иммунной системы - кау
EP98946052A EP1012270A2 (fr) 1997-09-12 1998-09-11 Kay, nouvelle proteine du systeme immunitaire
IS5375A IS5375A (is) 1997-09-12 2000-02-11 KAY-nýstárlegt ónæmisprótín
NO20001240A NO20001240L (no) 1997-09-12 2000-03-09 Kay-A immunsystemprotein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
US60/058,786 1997-09-12

Publications (2)

Publication Number Publication Date
WO1999012964A2 WO1999012964A2 (fr) 1999-03-18
WO1999012964A3 true WO1999012964A3 (fr) 1999-05-27

Family

ID=22018915

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/019037 Ceased WO1999012964A2 (fr) 1997-09-12 1998-09-11 Kay, nouvelle proteine du systeme immunitaire

Country Status (17)

Country Link
EP (1) EP1012270A2 (fr)
JP (1) JP2001515711A (fr)
KR (1) KR20010023892A (fr)
CN (1) CN1269832A (fr)
AU (1) AU9315298A (fr)
BR (1) BR9812433A (fr)
CA (1) CA2303424A1 (fr)
EA (1) EA200000311A1 (fr)
EE (1) EE200000148A (fr)
HU (1) HUP0004034A3 (fr)
IL (1) IL134480A0 (fr)
IS (1) IS5375A (fr)
NO (1) NO20001240L (fr)
PL (1) PL339740A1 (fr)
SK (1) SK3532000A3 (fr)
TR (1) TR200000654T2 (fr)
WO (1) WO1999012964A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9982302B2 (en) 2011-02-28 2018-05-29 Genentech, Inc. Biological markers and methods for predicting response to B-cell antagonists

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
JP2002503444A (ja) * 1997-11-26 2002-02-05 イーライ・リリー・アンド・カンパニー リガンドファミリー遺伝子
WO1999033980A2 (fr) * 1997-12-30 1999-07-08 Chiron Corporation Membres de familles de tnf et de tnfr
US6297367B1 (en) * 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
CA2360062A1 (fr) 1999-01-25 2000-07-27 Biogen, Inc. Baff, agents bloquants associes et utilisation de ceux-ci pour stimuler et inhiber la reponse immunitaire des lymphocytes b et des immunoglobulines
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
NZ513290A (en) * 1999-02-23 2004-05-28 Human Genome Sciences Inc Neutrokine-alpha and neutrokine-alpha splice variant
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
AU4986700A (en) 1999-05-06 2000-11-21 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
SK288603B6 (sk) 1999-08-17 2018-10-01 Biogen Ma Inc. Polypeptid a protilátka viažuca sa na polypeptid
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
NZ520789A (en) 2000-02-11 2005-01-28 Biogen Inc Heterologous polypeptide of the TNF family
AU2048501A (en) 2000-02-16 2001-08-27 Genentech Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
AU2001263114A1 (en) 2000-05-12 2001-11-26 Amgen Inc Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
EP2281843B1 (fr) 2000-06-16 2016-10-12 Human Genome Sciences, Inc. Anticorps se liant de maniere immunospecifique a un stimulateur de lymphocyte B (BLyS)
CA2419661A1 (fr) * 2000-08-15 2002-03-07 Guo-Liang Yu Neutrokine-alpha et variant d'epissage de neutrokine-alpha
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
PL393317A1 (pl) 2001-05-11 2011-05-23 Amgen Inc. Peptydy oraz pokrewne cząsteczki wiążące TALL-1
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
CA2520097C (fr) 2003-03-28 2014-10-07 Biogen Idec Ma Inc. Recepteurs baff tronques
PL1631313T3 (pl) 2003-06-05 2015-08-31 Genentech Inc Terapia skojarzona zaburzeń z komórek B
EP1675609A1 (fr) 2003-10-20 2006-07-05 Biogen Idec MA Inc. Regimes therapeutiques pour antagonistes baff
AU2004315198A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of BCMA and uses thereof
SG165344A1 (en) 2004-10-05 2010-10-28 Genentech Inc Method for treating vasculitis
NZ583905A (en) 2004-10-13 2011-12-22 Univ Washington Use of BAFF to Treat Sepsis
EP1836224A1 (fr) 2004-12-23 2007-09-26 Laboratoires Serono S.A. Polypeptides de bcma et leur utilisation
KR20080056714A (ko) 2005-08-09 2008-06-23 지모제넥틱스, 인코포레이티드 ＴＡＣＩ―Ｉｇ 융합 분자를 사용하여 Ｂ―세포 악성종양을치료하는 방법
CA2618763A1 (fr) 2005-08-09 2007-02-15 Zymogenetics, Inc. Procedes pour le traitement et la prevention de proliferation cellulaire anormale par le biais de molecules de fusion taci
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
WO2007062090A2 (fr) 2005-11-23 2007-05-31 Genentech, Inc. Procedes et compositions lies a des analyses de lymphocytes b
WO2007123765A2 (fr) 2006-03-31 2007-11-01 Human Genome Sciences Inc. NEUTROKINE-ALPHA et variant d'epissage de la neutrokine-alpha
JP2009537563A (ja) 2006-05-15 2009-10-29 アレス トレーディング ソシエテ アノニム Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法
WO2010075249A2 (fr) 2008-12-22 2010-07-01 Genentech, Inc. Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b
MX2012002766A (es) 2009-09-03 2012-04-02 Genentech Inc Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide.
WO2014122144A1 (fr) 2013-02-05 2014-08-14 Engmab Ag Anticorps bispécifiques anti-cd3ɛ et bcma
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
US10138251B2 (en) 2014-04-11 2018-11-27 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018325A1 (fr) * 1993-02-03 1994-08-18 N.V. Innogenetics S.A. Muteines de tnf-alpha et leur procede de preparation
WO1996040774A1 (fr) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes de lymphotoxines modifiees utilises comme preparations pharmaceutiques
WO1998018921A1 (fr) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine alpha
WO1998027114A2 (fr) * 1996-12-17 1998-06-25 Schering Corporation Antigenes de surface mammaliens et reactifs associes
EP0869180A1 (fr) * 1997-04-02 1998-10-07 Smithkline Beecham Corporation Un homologue de TNF, TL5

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018325A1 (fr) * 1993-02-03 1994-08-18 N.V. Innogenetics S.A. Muteines de tnf-alpha et leur procede de preparation
WO1996040774A1 (fr) * 1995-06-07 1996-12-19 Biogen, Inc. Complexes de lymphotoxines modifiees utilises comme preparations pharmaceutiques
WO1998018921A1 (fr) * 1996-10-25 1998-05-07 Human Genome Sciences, Inc. Neutrokine alpha
WO1998027114A2 (fr) * 1996-12-17 1998-06-25 Schering Corporation Antigenes de surface mammaliens et reactifs associes
EP0869180A1 (fr) * 1997-04-02 1998-10-07 Smithkline Beecham Corporation Un homologue de TNF, TL5

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9982302B2 (en) 2011-02-28 2018-05-29 Genentech, Inc. Biological markers and methods for predicting response to B-cell antagonists

Also Published As

Publication number Publication date
PL339740A1 (en) 2001-01-02
SK3532000A3 (en) 2001-12-03
JP2001515711A (ja) 2001-09-25
IL134480A0 (en) 2001-04-30
KR20010023892A (ko) 2001-03-26
TR200000654T2 (tr) 2000-07-21
EE200000148A (et) 2001-02-15
WO1999012964A2 (fr) 1999-03-18
CA2303424A1 (fr) 1999-03-18
NO20001240L (no) 2000-05-10
NO20001240D0 (no) 2000-03-09
EP1012270A2 (fr) 2000-06-28
IS5375A (is) 2000-02-11
HUP0004034A2 (en) 2001-03-28
BR9812433A (pt) 2000-09-26
CN1269832A (zh) 2000-10-11
HUP0004034A3 (en) 2002-08-28
AU9315298A (en) 1999-03-29
EA200000311A1 (ru) 2000-10-30

Similar Documents

Publication Publication Date Title
WO1999012964A3 (fr) Kay, nouvelle proteine du systeme immunitaire
WO1999012965A3 (fr) Nouveaux ligands de la famille des tnf
EP1591530B8 (fr) Ligand associé au facteur de nécrose tumorale
AU1102399A (en) Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
ZA947122B (en) Drug binding protein.
AU7678196A (en) Methods and compositions for the delivery of monomeric proteins
AU2526797A (en) Stimulation of immune response with low doses of interleukin-2
AU7705198A (en) Human tumor necrosis factor receptor tr10
AU7705098A (en) Human tumor necrosis factor receptor-like protein 8
AU7624598A (en) 1,4-diazabicyclo (2.2.2) Oct-2-ylmethyl derivatives, their preparation and the rapeutic application
AU5389096A (en) Human hematopoietic-specific protein
AU3003095A (en) Proteins associated with tumor necrosis factor receptor
AU1541699A (en) Human tumor necrosis factor-r2-like proteins
AU1568999A (en) Pharmaceutical compositions based on dalforpristin and quinupristin and preparation
AU1750997A (en) Obesity protein formulations
AU1705197A (en) Obesity protein formulations
AU4609693A (en) An interferon-alpha/beta binding protein its preparation and pharmaceutical compositions containing it
AU2243997A (en) Obesity protein formulations
AU5358894A (en) Recombinant alliinase, its preparation and pharmaceutical compositions comprising it
WO1998018818A3 (fr) Nouveaux inhibiteurs de l'hepatite b
AU1693995A (en) Phosphacan, nucleic acids encoding thereof and antibodies thereto
AU7478098A (en) Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies
ZA9610510B (en) Novel peptides, the preparation and use thereof.
AU6569998A (en) Obesity protein formulations
AU4483597A (en) Novel tumor proteins

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 134480

Country of ref document: IL

Ref document number: 98809023.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 93152/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2000-867

Country of ref document: CZ

Ref document number: 2000/00654

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: PA/A/2000/002410

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2303424

Country of ref document: CA

Ref document number: 2303424

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020007002576

Country of ref document: KR

Ref document number: 3532000

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2000 510769

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998946052

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 503849

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 200000311

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1998946052

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2000-867

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 1020007002576

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2000-867

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1998946052

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1020007002576

Country of ref document: KR